IOncology

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 31 to June 4. Multiple research advancements in urologic oncology were presented, including the SWOG S1600 study results shared by Dr. Jill Hamilton-Reeves. This study explored the impact of immune-enhancing nutrition on the outcomes of radical cystectomy. Oncology Frontier has compiled and summarized the relevant content for our readers.

The CHAARTED study demonstrated that early use of chemotherapy combined with androgen deprivation therapy (ADT+docetaxel) significantly improves survival for most patients with metastatic hormone-sensitive prostate cancer (HSPC). However, most patients eventually develop castration-resistant prostate cancer (CRPC) and require additional systemic treatment. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Christos Kyriakopoulos from the University of Wisconsin Carbone Cancer Center shared the results of the CHAARTED2 clinical study on cabazitaxel combined with abiraterone for metastatic prostate cancer. "Oncology Frontier" interviewed Professor Christos Kyriakopoulos to discuss treatment options for CRPC.

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31 to June 4 in Chicago, on the shores of Lake Michigan. Professor Jill Hamilton Reeves from the University of Kansas Medical Center shared the results of the SWOG S1600 study at the conference, exploring the impact of immunonutrition on the outcomes of radical cystectomy (RC). Oncology Frontier  interviewed Professor Jill Hamilton Reeves on-site to discuss the study results.

With advancements in cancer screening, diagnosis, and treatment, the survival period of cancer patients has significantly increased. Long-term management of cancer patients should not only focus on the primary tumor but also monitor for the occurrence of secondary primary tumors (SPTs) and multiple primary tumors through regular check-ups and screenings. Secondary primary tumors are defined as new independent malignant tumors that arise in different locations following treatment for an initial malignancy, and they are not recurrences or metastases of the first primary tumor. Various factors may contribute to the development of SPTs, such as age, obesity, genetic susceptibility, the stage at diagnosis of the first primary tumor, and environmental exposure. Previous studies have shown that the incidence of SPTs in cancer patients ranges from 8-16%, varying by tumor site . SPTs pose a significant threat to cancer patients' survival, accounting for 55% of cancer-related deaths .

In the field of hematologic oncology, treating acute myeloid leukemia (AML) has always been challenging, especially for relapsed or refractory patients. The limitations of traditional chemotherapy underscore the urgent need for innovative treatments. With advancements in immunotherapy, CAR-T cell therapy has introduced new breakthroughs in AML treatment. The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31 to June 4 in Chicago, USA. The "Phase I Study of Performance-Enhanced CD33 CAR-T Cells in Relapsed or Refractory AML Patients" was presented as a poster, aiming to explore the safety and preliminary efficacy of a novel CAR-T cell therapy in this patient group. "Oncology Frontier - Hematology Frontier " invited the study’s first author, Director Jing Pan from Beijing GoBroad Boren Hospital, to provide an in-depth interpretation of the research and share insights into advancements in AML diagnosis and treatment.

In this "Man Talks Breast Cancer: ASCO Special," Professor Man Li's team from The Second Affiliated Hospital of Dalian Medical University has selected the latest ASCO studies on HR+ advanced breast cancer, covering topics such as cross-line treatment with CDK4/6 inhibitors, novel ADCs combined with ICIs, and comparing CDK4/6 inhibitors + ET with chemotherapy in premenopausal women. These can provide more valuable insights for clinical practice.

Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy, presenting significant challenges in treatment strategies and prognosis management for clinicians. At this year’s ASCO conference, several AML studies were presented. This article highlights three of them, covering the importance of frailty assessment, exploration of shortened treatment regimens, and interim results of new therapeutic agents. These advancements not only offer new insights into treatment strategies but also bring hope to patients.

With advancements in cancer screening, diagnosis, and treatment, the survival period of cancer patients has significantly increased. Long-term management of cancer patients should not only focus on the primary tumor but also monitor for the occurrence of secondary primary tumors (SPTs) and multiple primary tumors through regular check-ups and screenings. Secondary primary tumors are defined as new independent malignant tumors that arise in different locations following treatment for an initial malignancy, and they are not recurrences or metastases of the first primary tumor. Various factors may contribute to the development of SPTs, such as age, obesity, genetic susceptibility, the stage at diagnosis of the first primary tumor, and environmental exposure. Previous studies have shown that the incidence of SPTs in cancer patients ranges from 8-16%, varying by tumor site . SPTs pose a significant threat to cancer patients' survival, accounting for 55% of cancer-related deaths .

The 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) was grandly held in Chicago, USA, from May 31 to June 4, 2024. As a premier global event, ASCO gathers oncology experts from around the world to discuss the latest advancements and future trends in the field. At this year's ASCO conference, several studies led by Professor Pei Dong from the Sun Yat-sen University Cancer Prevention and Treatment Center were selected, making a significant impact on the international stage. These studies not only represent new progress in the field of urologic oncology in China but also contribute to the global development of urologic oncology. "Oncology Frontier" has summarized these studies for our readers.

Hormone receptor-positive (HR+) breast cancer accounts for about 70% of all breast cancers. With endocrine therapy as the foundation, chemotherapy, targeted therapy, novel antibody-drug conjugates (ADCs), and immune checkpoint inhibitors (ICIs) provide a wealth of treatment options for HR+ advanced breast cancer patients, also offering more potential combinations for clinical practice. In this "Man Talks Breast Cancer: ASCO Special," Professor Man Li's team from The Second Affiliated Hospital of Dalian Medical University has selected the latest ASCO studies on HR+ advanced breast cancer, covering topics such as cross-line treatment with CDK4/6 inhibitors, novel ADCs combined with ICIs, and comparing CDK4/6 inhibitors + ET with chemotherapy in premenopausal women. These can provide more valuable insights for clinical practice.